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Abstract
Background The prevalence of asthma has increased both among children and adults during the latter half
of the 20th century. The prevalence among adults is affected by the incidence of asthma not only in
childhood but also in adulthood. Time trends in asthma incidence have been poorly studied.
Aims The aim of this study was to review the incidence of adult-onset asthma from 1996 to 2006 and
2006 to 2016 and compare the risk factor patterns.
Methods In the Obstructive Lung Disease in Northern Sweden (OLIN) studies, two randomly selected
population-based samples in the 20–69-year age group participated in postal questionnaire surveys about
asthma in 1996 (n=7104, 85%) and 2006 (n=6165, 77%). A 10-year follow-up of the two cohorts with the
same validated questionnaire was performed, and 5709 and 4552 responded, respectively. Different
definitions of population at risk were used in the calculations of asthma incidence. The protocol followed a
study performed between 1986 and 1996 in the same area.
Results The crude incidence rate of physician-diagnosed asthma was 4.4 per 1000 person-years (men 3.8,
women 5.5) from 1996 to 2006, and 4.8 per 1000 person-years (men 3.7, women 6.2) from 2006 to 2016.
When correcting for possible under-diagnosis at study entry, the incidence rate was 2.4 per 1000 person-
years from 1996 to 2006 and 2.6 per 1000 person-years from 2006 to 2016. The incidence rates were
similar across age groups. Allergic rhino-conjunctivitis was the main risk factor for incident asthma in both
observation periods (risk ratio 2.4–2.6).
Conclusions The incidence of adult-onset asthma has been stable over the last two decades and has remained
at a similar level since the 1980s. The high incidence contributes to the increase in asthma prevalence.
Introduction
The prevalence of asthma is frequently studied, and a consistent pattern of a worldwide increase during the
latter half of the 20th century has been reported, although the increase may have levelled off in some areas
[1, 2]. The reason for the increase is unclear, but changes in lifestyle and environments and rapid
urbanisation may have contributed [1, 3–5]. Prevalence is mainly a function of incidence and remission.
In adulthood, asthma is regarded as a chronic disease due to low remission [6, 7]. The prevalence of
asthma among adults is not only a result of the high incidence in childhood and adolescence [8–11] with
persistence into adulthood, but is also due to the relatively high incidence in adulthood [4, 12–24].
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However, incidence studies of adult-onset asthma are scarce, particularly longitudinal population-based
studies.
Comparing incidence rates of asthma is complex as the results are highly sensitive to the age of the study
population and the methods used. Reported incidence estimates vary substantially but are higher among
children and teenagers, 10–30 per 1000 person-years [8–11, 20], than among adults, 0.2–5 per 1000
person-years [4, 12–24]. Results from retrospective [11, 13, 22, 24, 25] and register studies [13] tend to
generate lower incidence rates than prospective studies [11–21, 25]. The definition of both the outcome
and the population at risk significantly influences the incidence rate [12, 15, 18, 19], which highlights the
importance of using the same methods and definitions to enable comparisons of results from different
studies and over time. Three studies carried out in Sweden and neighbouring countries, of which one was
in the same area as the current study, using identical methods, reported similar incidence rates of
physician-diagnosed asthma among adults from the 1980s up until 2006 of 2–3 per 1000 person-years
[15, 16, 18], but it is unknown if the incidence has changed since. As the prevalence of asthma in adults
has increased in Sweden over the last decades [2, 26], we hypothesised that the incidence of adult-onset
asthma is still high or has even increased during the same period. Thus, the main aim of the current study
was to estimate the incidence of adult-onset asthma during the period 1996 to 2016 by surveys of two
cohorts each followed for 10 years, one from 1996 to 2006 and the other from 2006 to 2016. A further aim
was to identify risk factors for adult-onset asthma.
Materials and methods
Study population
The study was performed within the Obstructive Lung Disease in Northern Sweden (OLIN) Studies.
All surveys were approved by the Regional Ethical Review Board at Umeå University.
The present paper is based on two random population samples, each followed for 10 years. The first
sample consists of participants from a postal questionnaire survey performed in 1996 of a general
population sample aged 20–69 years (n=7104, 85% response rate) [2]. This cohort was followed-up with
the same questionnaire in 2006, when 5709 individuals participated (80% response rate). The second
sample was recruited in 2006 using identical methods (n=6165, 77% response rate) [2], and followed-up in
2016 (n=4552, 74% response rate). Individuals from these two cohorts that participated both at baseline
and at the follow-up constitute the study populations in the current paper: n=5709 from the cohort
recruited in 1996 and n=4552 from the cohort recruited in 2006 (table 1). The surveys were all performed
during the same time period from January to May. We have previously published incidence rates of
adult-onset asthma based on a cohort recruited in 1986 in similar age groups and in the same area, which
was followed-up in 1992 [12] and 1996 [15]. The calculations of incidence in the current paper followed
the same protocol as that used in these previous studies.
Questionnaire
The OLIN questionnaire was used in all surveys. It was originally developed from a British Medical
Research Council questionnaire and has been validated against physiological variables [27]. It has been
used in the OLIN studies since 1986 and frequently in other studies of asthma and respiratory diseases in
Sweden and other countries [18, 19, 24, 26].
TABLE 1 Study population: invited and participated by sex in the two cohorts followed over 10 years
Cohort recruited in 1996 Cohort recruited in 2006
Women Men All Women Men All
Invited n 3982 4351 8333 3843 4154 7997













2006 n 3336 3438 6774
2016 n 3001 2817 5818
Participated both in 1996 and 2006 n 2876 2833 5709
Participated both in 2006 and 2016 n 2389 2163 4552
% of participants 82.9 78.8 80.4 76.2 71.4 73.8
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Definitions
The main outcome was physician-diagnosed asthma. The definitions for asthma and respiratory symptoms
were based on the following questions:
1. Physician-diagnosed asthma: “Have you been diagnosed as having asthma by a physician?”
2. Ever asthma: “Have you ever had asthma?”
3. Asthma medication use: “Do you currently use asthma medicines (on a regular basis or as needed)?”
4. Family history of asthma: “Have any of your parents or siblings asthma, or have they had asthma?”
5. Recurrent wheeze: “Do you usually have wheezing or whistling in your chest when breathing?”
6. Attacks of shortness of breath (SOB): Affirmative answer to both “Do you presently have, or have had
in the last 10 years, asthma symptoms (intermittent breathlessness or attacks of shortness of breath; the
symptoms may exist simultaneously with or without cough or wheezing)” and “Have you had these
problems within the last year?”
7. Allergic rhino-conjunctivitis: “Do you have or have you had allergic nose or eye problems (hay
fever)?”
8. Smoking habits: Smoking habits were divided into nonsmokers, ex-smokers (quit smoking at least
12 months prior to the survey) and smokers (smoked during the 12 months preceding the survey).
Classification of socioeconomic status was based on main occupation and categorised into three groups:
professionals, non-manual workers and manual workers according to classifications by Statistics Sweden.
Statistical analyses
The analyses were performed using the software IBM SPSS Statistics for Windows, v26 (Armonk,
New York, NY, USA). Missing answers of specific questions was low in all surveys, <5%. Internal
missing about asthma and respiratory symptoms was treated as a negative response while internal missing
about exposures was treated as missing. The chi-square test was used to test for differences in proportions
and the t-test for differences in means. Poisson regression analysis with physician-diagnosed asthma as
outcome was utilised to estimate risk ratios (RR) with 95% confidence intervals. The models were
analysed both unadjusted and adjusted with age, sex, allergic rhino-conjunctivitis, family history of
asthma, smoking habits and socioeconomic status included as covariates.
The cumulative incidence of physician-diagnosed asthma was estimated from two models of defining the
population at risk. In model A, individuals with any of the following variables at baseline were excluded
from the population at risk: physician-diagnosed asthma, ever having had asthma, asthma medication use,
recurrent wheeze or attacks of SOB lasting 12 months. In model B, individuals were excluded from the
population at risk if reporting having physician-diagnosed asthma at baseline. The cumulative incidence of
asthma medication use and recurrent wheeze was also estimated by models A and B, and additionally by a
third model C, where the population at risk excluded those reporting asthma medication use at baseline
when asthma medication use was analysed as the outcome variable, and where the population at risk
excluded those reporting recurrent wheeze at baseline when recurrent wheeze was the outcome. As we did
not have complete data on person-years, we used the cumulative incidence over the 10-year observation
period in each cohort to estimate annual incidence rate by assuming the incidence to be constant. The
estimated annual incidence rate was calculated as:
Incidence rate ¼ a
(10 (b (a=2)))
where a is the number of incident cases and b the number of subjects in the population at risk at the start
of the study, as also estimated in other studies [15, 18, 19].
Results
Baseline characteristics of the cohorts
In both cohorts the response rate was higher among women both at baseline and at the follow-ups (table 1).
The mean age of the individuals was 44.6 years in the cohort recruited in 1996 and 47.7 years in the cohort
recruited in 2006. Smoking was more common in the 1996 cohort than the 2006 cohort (27.4% versus
19.3%). Women reported significantly higher prevalence of attacks of SOB, allergic rhino-conjunctivitis and
use of asthma medication than men in both cohorts (table 2).
Incidence rates
According to model A, the incidence rate of physician-diagnosed asthma for the period 1996 to 2006 was
2.4 per 1000 person-years (in total 108 new cases during the 10-year follow-up) with minor differences
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between sex and age groups. Incidence of asthma medication use was higher among women than men
(4.7 per 1000 person-years versus 3.4 per 1000 person-years, p=0.028). The incidence rate of asthma for
the period 2006 to 2016 was 2.6 per 1000 person-years (in total 93 new cases) and was higher among
women than men (3.5 per 1000 person-years versus 1.7 per 1000 person-years, p=0.001). The incidence of
asthma medication use was also higher among women than men (5.7 per 1000 person-years versus 3.3 per
1000 person-years, p=0.001) (table 3).
According to model B, the incidence of physician-diagnosed asthma for the period 1996 to 2006 was
4.4 per 1000 person-years (in total 225 new cases), and the incidence of asthma medication use was
7.4 per 1000 person-years. For the period 2006 to 2016 the corresponding incidence rates were 4.8 per
1000 person-years (in total 188 new cases) and 8.3 per 1000 person-years, respectively. These incidence
estimates were all significantly higher among women (table 3).
According to model C, where the population at risk only excluded those reporting the outcome variable at
baseline, the incidence rates of asthma medication use and recurrent wheeze were between the estimations
from models A and B. The incidence of recurrent wheeze did not differ by sex in any model or
observation period (table 3).
Risk factors and respiratory symptoms of incident asthma
In an adjusted Poisson regression analysis, allergic rhino-conjunctivitis was a significant risk factor for
incident physician-diagnosed asthma, defined by model A, in both observation periods, with RR 2.62
(95% CI 1.69–4.07) and RR 2.39 (95% CI 1.48–3.87), respectively (table 4). Female sex was a significant
risk factor in the observation period 2006 to 2016 (RR 1.99 (95% CI 1.22–3.25)), but not from 1996 to
2006. Family history of asthma was a borderline risk factor for the period 1996 to 2006 (RR 1.50
(95% CI 0.93–2.43)), but significant from 2006 to 2016 (RR 1.75 (95% CI 1.05–2.90)). Ex-smoking was
a borderline risk factor from 1996 to 2006.
The same analysis as above yielded a closely similar pattern also according to model B with family history
of asthma, allergic rhino-conjunctivitis, female sex and ex-smoking as significant risk factors for incident
physician-diagnosed asthma during the period 1996 to 2006. The same risk factors, except ex-smoking,
were found for the period 2006 to 2016 (supplementary table S1).
Among individuals with adult-onset asthma in the cohort observed from 1996 to 2006, 70% reported
attacks of SOB in the last 12 months and 43% allergic rhino-conjunctivitis, and 83% used asthma
medication at the follow-up in 2006. The corresponding figures for individuals with adult-onset asthma in
the cohort observed from 2006 to 2016 were 65%, 44% and 80%, respectively, and these figures did not
differ significantly between incident cases in the two cohorts.
TABLE 2 Characteristics at recruitment: mean age and prevalence of asthma and respiratory symptoms, smoking habits and socioeconomic group
in the two cohorts by sex
Cohort recruited in 1996# Cohort recruited in 2006¶
Women Men All p-value+ Women Men All p-value+
Age mean (SD) 44.8 (13.5) 44.4 (13.2) 44.6 (13.3) 0.249 47.7(13.2) 47.6 (13.1) 47.7 (13.1) 0.731
Smoking habits %
Smoker 27.7 23.9 25.8 <0.001 20.5 14.2 17.5 <0.001
Ex-smoker 19.0 25.0 22.0 23.4 23.9 23.6
Nonsmoker 53.3 51.1 52.2 56.1 62.0 58.9
Physician-diagnosed asthma % 8.6 9.1 8.8 0.461 12.1 9.9 11.1 0.016
Asthma medication % 11.3 9.6 10.5 0.029 13.5 10.8 12.2 0.005
Recurrent wheeze % 13.2 12.2 12.7 0.274 11.1 11.7 11.4 0.584
Attacks of shortness of breath % 15.4 12.5 13.9 0.002 14.1 11.9 14.3 0.026
Allergic rhino-conjunctivitis % 24.7 22.2 23.4 0.029 27.4 22.8 25.2 <0.001
Family history of asthma % 24.6 18.6 21.6 <0.001 25.5 19.8 22.8 <0.001
Socioeconomic group %
Professionals 2.8 7.6 5.3 <0.001 5.5 7.7 6.6 <0.001
Non-manual workers 43.7 27.8 35.6 47.4 30.1 39.1
Manual workers 53.5 64.6 59.1 47.1 62.1 54.3
#: n=5709; ¶: n=4552; +: p-value for differences by sex, p-values in bold indicate statistical significance.
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TABLE 3 Incidence rate (n per 1000 person-years) of different asthma variables by age group and sex and by use of different definitions of population at risk
Outcome Cohort followed from 1996 to 2006 p-value# Cohort followed from 2006 to 2016 p-value#
Age years Sex Age years Sex
20–39 40–59 60–69 F M All¶ 20–39 40–59 60–69 F M All¶
Model A Physician-diagnosed asthma 2.6 2.4 2.6 2.7 2.2 2.4 0.285 2.8 2.6 2.5 3.5 1.7 2.6 0.001
Asthma medication use 4.4 3.9 3.3 4.7 3.4 4.0 0.028 4.8 4.7 3.9 5.7 3.3 4.5 0.001
Recurrent wheeze 4.9 4.6 5.5 4.5 5.1 4.8 0.396 4.5 5.9 4.9 5.3 5.2 5.3 0.874
Model B Physician-diagnosed asthma 4.4 4.5 4.1 5.2 3.6 4.4 0.008 4.8 4.4 5.5 5.8 3.6 4.8 0.001
Asthma medication use 7.6 7.4 6.3 9,0 5.6 7.3 <0.001 8.5 8.0 8.6 10.2 6.2 8.3 <0.001
Recurrent wheeze 8.2 8.9 10.5 8.7 9.1 8.9 0.631 8.1 9.0 8.3 8.5 8.7 8.6 0.848
Model C Asthma medication use 6.2 5.7 5.2 7,0 4.6 5.8 <0.001 6.6 6.8 5.9 8.3 4.7 6.5 <0.001
Recurrent wheeze 6.0 6.3 7.9 6.3 6.6 6.5 0.698 7.8 7.1 6.2 7.4 6.8 7.1 0.473
Model A: excluded from population at risk were those who at baseline reported any of physician-diagnosed asthma, ever-asthma, current use of asthma medicine and recurrent wheeze. Model B:
excluded from population at risk were those who reported physician-diagnosed asthma at baseline. Model C: excluded from population at risk were those who at baseline reported the outcome
variable. F: females; M: males. #: p-value for differences in cumulative incidence by sex, p-values in bold indicate statistical significance; ¶: no statistical difference by study period of any of the



















The main finding of these prospective population-based cohort studies was that the incidence of
adult-onset asthma in northern Sweden was stable from 1996 to 2016, and at a similar level as that from
1986 to 1996 [12, 15]. Thus, the reported increase in asthma prevalence during recent decades is not
explained by an increase in adult-onset asthma incidence but by the stable and relatively high incidence
(2–3 per 1000 person-years). The incidence was consistently higher among women than men. In analyses
adjusted for covariates, allergic rhino-conjunctivitis was the main risk factor for adult-onset asthma in both
periods.
To the best of our knowledge we are the first to report about trends in adult-onset asthma incidence over
several decades. A review article including incidence studies from the 1950s to 1990s indicated an increase
in incidence rate with time; however, the methods varied substantially between the included studies [28].
Three longitudinal population-based studies performed in Sweden and neighbouring countries during the
1980s and 1990s with almost identical methods found an incidence rate of 2–3 per 1000 person-years
[15, 16, 18]. Our results, 2.4 per 1000 person-years from 1996 to 2006 and 2.6 per 1000 person-years
from 2006 to 2016, are in line with these studies, including the previous study in our region (figure 1)
[15], and indicate a continuing stable trend in incidence rate in Sweden as a whole. However, an incidence
rate of 2–3 per 1000 person-years in combination with low remission of asthma in adulthood [6, 7, 18] and
similar mortality among adults with asthma as in the general population means about 1% unit increase in
prevalence every 10 years and thus contribute to the slowly increasing prevalence of asthma among adults.
Only a limited number of incidence studies of adult-onset asthma are based on prospective longitudinal
population-based studies [12–21, 23]. These studies show considerable variation in results, 0.7–6 per 1000
person-years, due to variations in the study design [11, 13, 14, 25] and the definitions of the outcome and
the population at risk [12, 14–16, 18]. Studies ending up with high incidence rates have often not excluded
individuals with symptoms common in asthma from the population at risk. To enable valid comparisons
between different studies it is paramount to use identical methods.
Symptoms of asthma may occur several years before a diagnosis of asthma is made, and these symptoms
may reflect undiagnosed asthma in the population, which is why the incidence rate may be overestimated.
To reduce this bias it is reasonable to also exclude subjects reporting symptoms of asthma from the
population at risk. When comparing different populations at risk (model A versus B) we found that the
difference in incidence rate of physician-diagnosed asthma between the two models was much smaller in
the two current cohorts under study compared with the study from the 1980s, which was performed with
almost identical methods in the same area (figure 1). When using model B (not correcting for possible
under-diagnosis), the incidence of physician-diagnosed asthma was 4.4–4–8 per 1000 person-years in the
current cohorts, while it was 8 per 1000 person-years in the 1980s cohort [12]. This may reflect a decrease
TABLE 4 Risk factors for incident adult-onset physician-diagnosed asthma defined by model A
Independent variables Category Cohort followed from 1996 to 2006 Cohort followed from 2006 to 2016
Unadjusted Adjusted Unadjusted Adjusted
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Sex Men 1 1 1 1
Women 1.23 (0.84–1.79) 1.18 (0.77–1.79) 2.07 (1.34–3.21) 1.99 (1.22–3.25)
Family history of asthma No 1 1 1 1
Yes 1.78 (1.17–2.72) 1.50 (0.93–2.43) 2.10 (1.36–3.26) 1.75 (1.05–2.90)
Allergic rhino-conjunctivitis No 1 1 1 1
Yes 2.47 (1.65–3.69) 2.62 (1.69–4.07) 2.42 (1.58–3.71) 2.39 (1.48–3.87)
Smoking habits Nonsmokers 1 1 1 1
Ex-smokers 1.67 (1.06–2.62) 1.62 (0.99–2.67) 0.87 (0.58–1.58) 1.01 (0.59–1.75)
Smokers 1.42 (0.89–2.26) 1.38 (0.83–2.29) 0.79 (0.42–1.47) 0.89 (0.46–1.69)
Socioeconomic group Professionals 1 1 1 1
Non-manual workers 1.46 (0.45–4.80) 1.32 (0.40–4.37) 0.88 (0.37–2.12) 0.76 (0.31–1.89)
Manual workers 1.90 (0.60–6.05) 1.75 (0.55–5.60) 0.90 (0.38–2.12) 0.90 (0.38–2.13)
Data are presented as unadjusted and adjusted RR (95% CI) from Poisson regression models. Model A: excluded from population at risk were those
who at baseline reported any of physician-diagnosed asthma, ever-asthma, current use of asthma medicine and recurrent wheeze. The adjusted
regression models included incident physician-diagnosed asthma as outcome, and all variables presented in the table as independent variables.
Bold values indicate p<0.05.
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in under-diagnosis of asthma since the 1980s, probably due to changed diagnostic practice and higher
awareness of asthma in healthcare and society today [2, 26]. However, at the follow-up of our two current
cohorts in 2006 and 2016, individuals with incident asthma reported similar prevalence of symptoms of
asthma and use of asthma medication. This indicates a similar disease burden among individuals with
adult-onset asthma today as 10 years ago, which in part contradicts the suggested diagnostic drift regarding
asthma in healthcare. On the other hand, the major change may have occurred before the millennium shift
as a consequence of a Swedish national programme focusing on asthma during 1995, and perhaps even be
related to the start of the OLIN-research programme in the study area in 1986, resulting in increased
awareness of asthma in the society. Still, the higher incidence rate of use of asthma medication compared
with asthma diagnosis may indicate some under-diagnosis of asthma also today. Nevertheless, asthma
medication is also used in other respiratory diseases, such as bronchitis and COPD, which probably
contributes to the high incidence.
In line with previous studies, we found that women had a higher incidence of adult-onset asthma compared
with men (figure 2) [12–24, 29, 30]. This is in contrast to children, where the incidence is higher among
boys than girls [8, 9, 11, 22]. The reason for the sex differences is unclear but may be related to hormonal
status [29]. The obese-asthma phenotype, often found in adult-onset asthma among women [5, 29], may be


































Model A Model B
FIGURE 1 Incidence rate of physician-diagnosed asthma over three decades, from 1986 to 2016, estimated by
two different models of defining population at risk. Model A: excluded from population at risk were those who
at baseline reported physician-diagnosed asthma, ever-asthma, current use of asthma medicine and recurrent
wheeze. Model B: excluded from population at risk were those who reported physician-diagnosed asthma at


































FIGURE 2 Incidence rate of physician-diagnosed asthma by sex for three decades, from 1986 to 2016. Incident
cases were defined by model A in all cohorts. Model A: excluded from population at risk were those who at
baseline reported physician-diagnosed asthma, ever-asthma, current use of asthma medicine and recurrent
wheeze. #: LUNDBÄCK et al. [15].
https://doi.org/10.1183/23120541.00262-2021 7
ERJ OPEN RESEARCH ORIGINAL RESEARCH ARTICLE | P. RÄISÄNEN ET AL.
reported to be a predictor for persistent asthma from childhood to adulthood [32, 33], which is why it seems
that the increasing prevalence of asthma among adults is mainly driven by women, i.e. by lower remission
rate of childhood asthma and higher incidence rate of adult-onset asthma in women than in men.
Allergic rhino-conjunctivitis is a well-known risk factor for asthma [4, 17, 19, 21] and is a reasonable proxy
for allergic sensitisation, at least among younger and middle-aged adults [21]. In the current study it was the
strongest and most stable risk factor for asthma, which further strengthens the causality of the association.
Several previous studies have found smoking or ex-smoking associated with incidence of asthma [4, 10, 12,
15, 19, 23]. In the current study we found that, from 2006, neither smoking nor ex-smoking remained as risk
factors for incident asthma among adults. This change is probably a result of the considerable decrease in
smoking that has occurred during the last decades in Sweden [2, 26]. Not only has the prevalence of smoking
decreased, but also the number of cigarettes smoked per day has been reduced [2]. In contrast to previous
studies that have reported several markers for low socioeconomic status to be associated with incident asthma
[34–36], we did not find any consistent associations with socioeconomic status based on occupation.
However, though not significant, the RR for manual work was 1.75 in the 1996 cohort, while the RR was
close to 1 in the most recent cohort. This may be due to improvements in the working environment, but may
also be due to lack of power in our study, not allowing more detailed occupational classifications.
Several strengths support the validity of the results. First, we used two large population-based cohorts within the
same age-span and geographical area, and both cohorts were followed for 10 years. Second, the response rate
was high in both cohorts, both at recruitment and follow-up. Third, for high comparability with previous studies
[12, 15, 18] we used identical methods in the calculations of incidence, and these were based on the same
validated questionnaire [27]. Furthermore, the prospective design is, compared with retrospective studies, less
associated with recall bias [11, 25]. Although the internal validity can be regarded as high, the external validity
is unclear due to the lack of studies of trends in asthma incidence. A limitation worth noting is that despite the
large sample sizes of the cohorts and the relatively long follow-up, the study lacks power for subgroup analyses.
The studies were based on questionnaire data, which may have introduced some bias, and is why we cannot rule
out that some of those diagnosed as having asthma in reality had COPD. However, the incidence was similar
across all age groups. Another weakness is the limited information about risk factors such as body mass index
and education level, factors that have been associated with adult-onset asthma [4, 5, 29, 34].
Conclusion
Based on identical methods, the incidence of adult-onset asthma was stable from 1996 to 2016 and has
remained at an almost identical level since the 1980s. The observed high incidence in parallel with low
remission in adulthood contribute to the ongoing increase in prevalence of asthma among adults.
As previously found, the incidence was higher among women than men and allergic rhino-conjunctivitis
was the main risk factor.
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